Community-acquired pneumonia: is it time to shorten the antibiotic treatment?

References

• Bartlett JG, Dowell SF, Mandell LA et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin. Infect. Dis.31, 347–382 (2000).
   PubMed Web of Science ®Google Scholar
• Mandell LA. Epidemiology and etiology of community-acquired pneumonia. Infect. Dis. Clin. N. Am.18, 761–776 (2004).
   PubMed Web of Science ®Google Scholar
• File TM Jr, Garau J, Blasi F et al. Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia. Chest125, 1888–1901 (2004).
   PubMed Web of Science ®Google Scholar
• Segreti J, House HR, Siegel RE. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting. Am. J. Med.118(7 Suppl.), S21–S28 (2005).
   Google Scholar
• File TM Jr. Community-acquired pneumonia. Lancet362, 1991–2001 (2003).
   PubMed Web of Science ®Google Scholar
• Mills GD, Oehley MR, Arrol B. Effectiveness of β lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. Br. Med. J.330, 456 (2005).
   PubMed Web of Science ®Google Scholar
• Niederman MS, Mandell LA, Anzueto A et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am. J. Respir. Crit. Care. Med.163, 1730–1754 (2001).
   PubMed Web of Science ®Google Scholar
• Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis.44(Suppl. 2), S27–S72 (2007).
   PubMed Web of Science ®Google Scholar
• Mandell LA, Bartlett JG, Dowell SF et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin. Infect. Dis.37, 1405–1433 (2003).
   PubMed Web of Science ®Google Scholar
• Mandell LA, Marrie TJ, Grossman RF et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin. Infect. Dis.31, 383–421 (2000).
   PubMedGoogle Scholar
• Halm EA, Teirstein AS. Clinical practice. Management of community-acquired pneumonia. N. Engl. J. Med.347, 2039–2045 (2002).
   PubMed Web of Science ®Google Scholar
• Bjerre LM, Verheij TJ, Kochen MM. Antibiotics for community acquired pneumonia in adult outpatients. Cochrane Database Syst. Rev.CD002109 (2004).
   PubMedGoogle Scholar
• Shefet D, Robenshtok E, Paul M, Leibovici L. Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials. Arch. Intern. Med.165, 1992–2000 (2005).
   PubMed Web of Science ®Google Scholar
• BTS guidelines for the management of community acquired pneumonia in adults. Thorax56, IV1–IV64 (2001).
   PubMed Web of Science ®Google Scholar
• Contopoulos-Ioannidis DG, Ioannidis JP, Chew P, Lau J. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections. J. Antimicrob. Chemother.48, 691–703 (2001).
   PubMed Web of Science ®Google Scholar
• File TM Jr. Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia. Clin. Infect. Dis.39(Suppl. 3), S159–S164 (2004).
   PubMed Web of Science ®Google Scholar
• Hopkins S, Williams D. Five-day azithromycin in the treatment of patients with community-acquired pneumonia. Curr. Ther. Res. Clin. Exp.56, 915–925 (1995).
   Web of Science ®Google Scholar
• Socan M. Treatment of atypical pneumonia with azithromycin: comparison of a 5-day and a 3-day course. J. Chemother.10, 64–68 (1998).
   PubMed Web of Science ®Google Scholar
• Mandell LA, File TM Jr. Short-course treatment of community-acquired pneumonia. Clin. Infect. Dis.37, 761–763 (2003).
   PubMed Web of Science ®Google Scholar
• Kolditz M, Halank M, Hoffken G. Short-course antimicrobial therapy for community-acquired pneumonia. Treat. Respir. Med.4, 231–239 (2005).
   PubMedGoogle Scholar
• Bohte R, Van’t Wout JW, Lobatto S et al. Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community acquired pneumonia. Eur. J. Clin. Microbiol. Infect. Dis.14, 182–187 (1995).
   PubMed Web of Science ®Google Scholar
• Brion JP, Sedallian A, Le Noc P et al. Azithromycin versus josamycin: treatment of 89 acute pneumonia cases. Pathol. Biol. (Paris)38, 521–525 (1990).
   PubMedGoogle Scholar
• Kinasewitz G, Wood RG. Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia. Eur. J. Clin. Microbiol. Infect. Dis.10, 872–877 (1991).
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Sakayori S, Koike T et al. Clarithromycin-controlled randomized double-blind studies of azithromycin for treatment of pneumonia. Jpn. J. Chemother.43, 757–774 (1995).
   Google Scholar
• O’Doherty B, Muller O. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Eur. J. Clin. Microbiol. Infect. Dis.17, 828–833 (1998).
   PubMed Web of Science ®Google Scholar
• Rahav G, Fidel J, Gibor Y, Shapiro M. Azithromycin versus comparative therapy for the treatment of community acquired pneumonia. Int. J. Antimicrob. Agents24, 181–184 (2004).
   PubMed Web of Science ®Google Scholar
• Rizzato G, Montemurro L, Fraioli P et al. Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia. Eur. Respir. J.8, 398–402 (1995).
   PubMed Web of Science ®Google Scholar
• Schonwald S, Barsic B, Klinar I, Gunjaca M. Three-day azithromycin compared with ten-day roxithromycin treatment of atypical pneumonia. Scand. J. Infect. Dis.26, 706–710 (1994).
   PubMed Web of Science ®Google Scholar
• Schonwald S, Gunjaca M, Kolacny-Babic L et al. Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias. J. Antimicrob. Chemother.25(Suppl. A), 123–126 (1990).
   PubMed Web of Science ®Google Scholar
• Sopena N, Martinez-Vazquez C, Rodriguez-Suarez JR et al. Comparative study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of community-acquired pneumonia in adults. J. Chemother.16, 102–103 (2004).
   PubMed Web of Science ®Google Scholar
• Dunbar LM, Wunderink RG, Habib MP et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin. Infect. Dis.37, 752–760 (2003).
   PubMed Web of Science ®Google Scholar
• Leophonte P, File T, Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir. Med.98, 708–720 (2004).
   PubMed Web of Science ®Google Scholar
• Leophonte P, Choutet P, Gaillat J et al. Efficacy of a ten day course of ceftriaxone compared to a shortened five day course in the treatment of community-acquired pneumonia in hospitalized adults with risk factors. Med. Mal. Infect.32, 369–381 (2002).
   Web of Science ®Google Scholar
• Siegel RE, Alicea M, Lee A, Blaiklock R. Comparison of 7 versus 10 days of antibiotic therapy for hospitalized patients with uncomplicated community-acquired pneumonia: a prospective, randomized, double blind study. Am. J. Ther.6, 217–222 (1999).
   PubMedGoogle Scholar
• Tellier G, Niederman MS, Nusrat R et al. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J. Antimicrob. Chemother.54, 515–523 (2004).
   PubMed Web of Science ®Google Scholar
• File TM Jr, Niederman MS. Antimicrobial therapy of community acquired pneumonia. Infect. Dis. Clin. N. Am.18, 993–1016 (2004).
   PubMed Web of Science ®Google Scholar
• Restrepo MI, Anzueto A. Antimicrobial treatment of community acquired pneumonia. Clin. Chest Med.26, 65–73 (2005).
   PubMed Web of Science ®Google Scholar
• Pakistan Multicentre Amoxycillin Short Course Therapy (MASCOT) pneumonia study group. Clinical efficacy of 3 days versus 5 days of oral amoxicillin for treatment of childhood pneumonia: a multicentre double-blind trial. Lancet360, 835–841 (2002).
   PubMed Web of Science ®Google Scholar
• Agarwal G, Awasthi S, Kabra SK et al. Three day versus five day treatment with amoxicillin for non-severe pneumonia in young children: a multicentre randomised controlled trial. Br. Med. J.328, 791 (2004).
   PubMed Web of Science ®Google Scholar
• el Moussaoui R, de Borgie CA, van den Broek P et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. Br. Med. J.332, 1355 (2006).
   PubMed Web of Science ®Google Scholar
• Richter SS, Heilmann KP, Beekmann SE et al. The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations. Clin. Infect. Dis.40, 225–235 (2005).
   PubMed Web of Science ®Google Scholar
• Karchmer AW. Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US – an update. Clin. Infect. Dis.39(Suppl. 3), S142–S150 (2004).
   PubMed Web of Science ®Google Scholar
• Doern GV. Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States. Clin. Infect. Dis.33(Suppl. 3), S187–S192 (2001).
   PubMed Web of Science ®Google Scholar
• Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J. Antimicrob. Chemother.25(Suppl. A), 73–82 (1999).
   Google Scholar
• Schrag SJ, Pena C, Fernandez J et al. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. JAMA286, 49–56 (2001).
   PubMed Web of Science ®Google Scholar
• Kardas P. Patient compliance with antibiotic treatment for respiratory tract infections. J. Antimicrob. Chemother.49, 897–903 (2002).
   PubMed Web of Science ®Google Scholar
• Reyes H, Guiscafre H, Munoz O et al. Antibiotic noncompliance and waste in upper respiratory infections and acute diarrhea. J. Clin. Epidemiol.50, 1297–1304 (1997).
   PubMed Web of Science ®Google Scholar
• Cunha BA. Antimicrobial therapy of multidrug-resistant Streptococcus pneumoniae, vancomycin-resistant enterococci, and methicillin-resistant Staphylococcus aureus. Med. Clin. North Am.90, 1165–1182 (2006).
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Thornsberry C, Jones ME et al. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998–2002). Clin. Infect. Dis.36, 963–970 (2003).
   PubMed Web of Science ®Google Scholar
• Davidson R, Cavalcanti R, Brunton JL et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N. Engl. J. Med.346, 747–750 (2002).
   PubMed Web of Science ®Google Scholar
• Whitney CG, Farley MM, Hadler J et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N. Engl. J. Med.343, 1917–1924 (2000).
   PubMed Web of Science ®Google Scholar
• Powis J, McGeer A, Green K et al.In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002. Antimicrob. Agents Chemother.48, 3305–3311 (2004).
   PubMed Web of Science ®Google Scholar
• Clay KD, Hanson JS, Pope SD et al. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann. Intern. Med.144, 415–420 (2006).
   PubMed Web of Science ®Google Scholar
• Bartlett JG, Breiman RF, Mandell LA et al. Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America. Clin. Infect. Dis.26, 811–838 (1998).
   PubMed Web of Science ®Google Scholar
• Mandell LA. Update on community-acquired pneumonia: new pathogens and new concepts in treatment. Postgrad. Med.118, 35–46 (2005).
   PubMed Web of Science ®Google Scholar
• Li JZ, Winston LG, Moore DH, Bent S. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am. J. Med.120, 783–790 (2007).
   PubMed Web of Science ®Google Scholar
• Blasi F, Tarsia P. Value of short-course antimicrobial therapy in community-acquired pneumonia. Int. J. Antimicrob. Ag.26(Suppl. 3), 148–155 (2005).
   PubMedGoogle Scholar